

Executive Summary/Company History

Founded in October 2015, ABC *Life Sciences* is a development stage company with a unique nanoparticle drug-delivery platform that delivers drug of choice selectively to the kidneys. Our targeted approach has great therapeutic potential because direct delivery to kidneys can reduce the amount of active drug needed, as well as significantly reduce untoward side effects. The goal of ABC *Life Sciences* is to provide effective therapies for a range of kidney diseases. ABC *Life Sciences* is the proud winner of the Bench to Bedside Pitch Day in November 2015, sponsored by the Tri-Institutional Therapeutics Discovery Institute. ABC *Life Sciences* was also selected to participate in the Entrepreneurship Lab-NYC, 2016. ABC *Life Sciences* is based on technology developed at Memorial Sloan Kettering Cancer Center.

Unmet Need and Market

In the US alone, over 20 million people suffer from kidney problems. Despite the significant unmet medical need, there are currently no effective treatments and few in development. Supportive treatments or dialysis is the standard of care but neither is safe nor effective as kidneys do not fully recover, the rate of survival does not significantly improve and secondary complications often arise. The total market size for kidney disease in the US is \$92 billion. Due to an aging population, the disease state is increasing; thus, the commercial opportunity to treat many kidney diseases is rapidly increasing.

Novel technology → Many products

Our well-characterized nanoparticle that is made of FDA-approved material (PLGA-PEG) is selective to the kidneys and is not toxic to the kidney or any other organ. With our platform technology, we are able to produce many types of products. Establishing our first proof of concept internally will open a wide variety of external development opportunities. We anticipate collaborations with pharmacology, biotechnology and/or device companies to develop new molecular entities that need to be targeted to the kidneys.

Competitive Positioning

While there are several companies developing therapies for kidney diseases, none have a targeted approach that allows the drug to be delivered where it is most needed. This is why our technology predicts superior efficacy with fewer side effects.

Business Strategy/Milestones

We are seeking \$500K to establish our first proof of concept (prevention of cisplatin-induced acute kidney injury), Milestone #1, and upon partnership, \$35M in tranching financing. With these funds, we will successfully complete IND-enabling studies to reach Milestone #2 (IND-approval), Phase I (Milestone #3) and Phase IIa (Milestone #4) clinical trials. At this advanced stage of development, we anticipate licensing the product to the partnering company.

ABC *Life Sciences* is building a leadership team that brings experience, expertise and a strong commitment to our mission in developing effective therapies for kidney diseases. We are expanding our team to include biomaterials and nanotechnology experts and a business advisor.

Management

Paige Yellen, Ph.D. (Founder and CEO) is a biotechnology entrepreneur who enrolled in the Tri-Institutional Bench to Bedside Course to begin her first pursuit in commercializing the nanoparticle technology invented at Memorial Sloan Kettering Cancer Center (MSKCC). She is a recent post-doctoral fellow in the Department of Molecular Pharmacology and Chemistry at MSKCC with a strong background in molecular pharmacology and chemistry.

Ryan Williams, Ph.D. (Senior Research Scientist) is a co-inventor of the technology and a post-doctoral fellow at Memorial Sloan Kettering who devises the nanoparticles and has expertise in pharmacology, nanotechnology, and molecularly targeted therapeutics.

Advisors

Dan Heller, Ph.D. (Scientific Advisor) is the inventor of the nanoparticle technology and is a principal investigator at Memorial Sloan Kettering Cancer Center. His research focuses on biomaterials and nanoscale engineering for molecular sensors and targeted therapeutics.

Edgar Jaimes, M.D. (Medical Advisor) is the Chief of Nephrology at Memorial Sloan Kettering Cancer Center. He focuses on the treatment of patients who develop kidney diseases resulting from chemotherapy.